Threshold Pharmaceuticals

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 55 in Threshold Pharmaceuticals

  1. Threshold Pharmaceuticals, Inc. Reports Preclinical Data Suggesting...Read the original story

    Wednesday Apr 22 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced preclinical data on TH-4000, its proprietary, molecularly-targeted, hypoxia-activated, irreversible epidermal growth factor receptor tyrosine kinase inhibitor suggesting that TH-4000 may overcome resistance to therapy with conventional EGFR-TKIs. In a xenograft model of non-small cell lung cancer in which both wild-type EGFR and mutant EGFR are present , TH-4000 was more active than the conventional EGFR-TKI erlotinib.

    Comment?

  2. Human clinical trials planned for new anti-cancer compoundRead the original story

    Wednesday Apr 22 | Scoop

    After 10 years of discovery and research, two University of Auckland medical oncology researchers along with their dedicated teams have developed a new anti-cancer compound that will advance to human phase two clinical trials. The co-inventors of the compound TH-4000, Dr Adam Patterson and Dr Jeff Smaill, senior academics from the Auckland Cancer Society Research Centre and the Maurice Wilkins Centre, have collaborated with a NASDAQ-listed American bio-technology company, Threshold Pharmaceuticals, to advance the compound to this stage.

    Comment?

  3. Kiwi cancer drug rescuedRead the original story w/Photo

    Wednesday Apr 22 | The New Zealand Herald

    ... for the types of cancer they hoped to target in further trials. However a new sponsor, US company Threshold Pharmaceuticals, soon picked up TH-4000. It had been a roller-coaster ride, but the drug was now with the world's leading biotechnology ...

    Comment?

  4. NeuroVive: Development Of NVP014 For The Treatment Of Stroke Enters New Phase In Collaboration WithRead the original story

    Thursday Apr 16 | BioSpace

    Threshold Pharmaceuticals, Inc. , today announced that it will host an Analyst and Investor Day on Friday, April 24, 2015, from 11:30 AM to 1:30 PM Eastern Time in New York City. Members of Threshold's senior management team will be joined by other research and clinical leaders in the field of tumor hypoxia, hypoxia-activated prodrugs, and next-generation epidermal growth factor receptor tyrosine kinase inhibitor therapy to discuss its clinical development programs for evofosfamide and TH-4000.

    Comment?

  5. Threshold Pharmaceuticals to Host Analyst and Investor Day on April 24 in New York CityRead the original story w/Photo

    Thursday Apr 16 | Market Wire

    Members of Threshold's senior management team will be joined by other research and clinical leaders in the field of tumor hypoxia, hypoxia-activated prodrugs, and next-generation epidermal growth factor receptor tyrosine kinase inhibitor therapy to discuss its clinical development programs for evofosfamide and TH-4000. Guest speakers scheduled to give presentations at this event include Stephen V. Liu, M.D., Assistant Professor of Medicine, Georgetown University Medical Center; Adam Patterson, Ph.D., Head of Translational Therapeutics, University of Auckland, New Zealand; and Jeff Smaill, Ph.D., Senior Medicinal Chemist, University of Auckland, New Zealand.

    Comment?

  6. "Myelofibrosis - Pipeline Review, H1 2015" now available at Fast Market ResearchRead the original story

    Saturday Mar 28 | PR-inside.com

    ... Inc., Pfizer Inc., PharmaEssentia Corporation, Promedior, Inc., Stemline Therapeutics, Inc., Threshold Pharmaceuticals, Inc. About Global Markets Direct Global Markets Direct is a leading provider of global business intelligence and market analysis. ...

    Comment?

  7. Threshold Pharmaceuticals, Inc. To Present Data Supporting Planned...Read the original story

    Mar 18, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. , today announced it will present data on its investigational anti-cancer drugs at the annual meeting of the American Association for Cancer Research 2015 being held April 18-22, 2015, in Philadelphia, Pennsylvania. The company will present clinical and preclinical data on TH-4000, its proprietary, hypoxia-activated irreversible epidermal growth factor receptor tyrosine kinase inhibitor , which the company believes support its two planned Phase 2 proof-of-concept clinical trials of TH-4000.

    Comment?

  8. Threshold Pharmaceuticals to Present Data Supporting Planned Phase 2...Read the original story w/Photo

    Mar 19, 2015 | Market Wire

    The company will present clinical and preclinical data on TH-4000, its proprietary, hypoxia-activated irreversible epidermal growth factor receptor tyrosine kinase inhibitor , which the company believes support its two planned Phase 2 proof-of-concept clinical trials of TH-4000. In addition, preclinical data evaluating the potential use of evofosfamide in a variety of tumor types will be presented by Threshold and Merck KGaA, Darmstadt, Germany, the company's partner for the development and commercialization of evofosfamide.

    Comment?

  9. New Market Report: Threshold Pharmaceuticals, Inc. (THLD) - Financial ...Read the original story

    Mar 4, 2015 | PR-inside.com

    2015-03-04 22:24:05 - Recently published research from GlobalData, "Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT Analysis Review", is now available at Fast Market Research Threshold Pharmaceuticals, Inc. (Threshold) is a ...

    Comment?

  10. Threshold Pharmaceuticals, Inc. Reports Fourth Quarter And Year End...Read the original story

    Mar 2, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. , today reported financial results for the fourth quarter and year ended December 31, 2014. Revenue for the fourth quarter and year ended December 31, 2014 was $3.7 million and $14.7 million, respectively.

    Comment?

  11. Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 Cowen Health Care ConferenceRead the original story

    Feb 24, 2015 | Freshnews

    02/24/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 2015 Cowen Health Care Conference on March 2, 2015, at 4:50 p.m. Eastern ...

    Comment?

  12. Threshold Pharmaceuticals, Inc. Announces Pricing Of $30 Million...Read the original story

    Feb 12, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced the pricing of an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common stock. The combined offering price of each share of common stock and accompanying warrant was $3.62.

    Comment?

  13. Threshold Pharmaceuticals Raises Cash - An Inside Look At The DealRead the original story w/Photo

    Feb 12, 2015 | Seeking Alpha

    Threshold pharmaceuticals announced pricing on a $30 million financing today. The company sold 8.3 million shares that each come with one warrant having a 5-year expiry, and an exercise price of $10.86.

    Comment?

  14. Threshold Pharmaceuticals Announces Pricing of $30 Million Offering of Common Stock and WarrantsRead the original story

    Feb 12, 2015 | Freshnews

    02/12/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the pricing of an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common ...

    Comment?

  15. MLV & Co Reiterates "Buy" Rating for Threshold PharmaceuticalsRead the original story

    Feb 9, 2015 | AmericanBankingNews.com

    ... question as to whether the prolongation of mPFS and median overall survival (mOS) reported with Threshold Pharmaceuticals' TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in a Phase II trial would be improved if doxorubicin was ...

    Comment?

  16. The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here?Read the original story

    Jan 28, 2015 | InvestorIdeas.com

    ... million ($242M), Synta Pharmaceuticals Corp. (SNTA:NASDAQ) , with a market cap of about $278M and Threshold Pharmaceuticals Inc. (THLD:NASDAQ) , with a market cap of about $235M. The theme? "They're all oncology companies," Zavoico said. "Synta and ...

    Comment?

  17. "Threshold Pharmaceuticals, Inc. (THLD) - Pharmaceuticals &...Read the original story

    Dec 31, 2014 | PR-inside.com

    Threshold Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops and commercializes therapeutics for the treatment of cancer.

    Comment?

  18. Threshold Pharmaceuticals PT Set at $14.50 by MLV & CoRead the original story

    Dec 19, 2014 | AmericanBankingNews.com

    ... & Co 's price objective suggests a potential upside of 364.74% from the stock's previous close. Threshold Pharmaceuticals ( NASDAQ:THLD ) traded up 0.48% on Friday, hitting $3.135. The stock had a trading volume of 560,298 shares. Threshold ...

    Comment?

  19. Neuroendocrine Tumors - Pipeline Review, H2 2014 - New Market Study PublishedRead the original story

    Dec 15, 2014 | PR-inside.com

    ... Inc., Progenics Pharmaceuticals, Inc., Sompharmaceuticals S.A., Tekmira Pharmaceuticals Corp., Threshold Pharmaceuticals, Inc. About Global Markets Direct Global Markets Direct is a leading provider of global business intelligence and market ...

    Comment?

  20. Threshold Pharmaceuticals, Inc. Release: Encouraging Initial Data...Read the original story

    Dec 7, 2014 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma . The median number of prior therapies was 8 .

    Comment?